Clinical Trial Update: Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating topical cantharidin (VP-102) for treatment of common warts (verruca vulgaris) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Verruca Vulgaris

Drugs mentioned

• VP-102 (cantharidin topical solution)

Snippet

Sponsor: Verrica Pharmaceuticals Inc. | Conditions: Common Warts, Common Warts (Verruca Vulgaris) | Phase 3 | Status: RECRUITING